[go: up one dir, main page]

GB2453084A - Novel polypeptides for an anti-viral treatment - Google Patents

Novel polypeptides for an anti-viral treatment Download PDF

Info

Publication number
GB2453084A
GB2453084A GB0900707A GB0900707A GB2453084A GB 2453084 A GB2453084 A GB 2453084A GB 0900707 A GB0900707 A GB 0900707A GB 0900707 A GB0900707 A GB 0900707A GB 2453084 A GB2453084 A GB 2453084A
Authority
GB
United Kingdom
Prior art keywords
novel polypeptides
viral treatment
viral
treatment
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0900707A
Other versions
GB0900707D0 (en
Inventor
Taian Cui
Chum Mok Puah
Oi Wah Liew
Siew Hui Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Singapore Polytechnic
Original Assignee
Singapore Polytechnic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Polytechnic filed Critical Singapore Polytechnic
Publication of GB0900707D0 publication Critical patent/GB0900707D0/en
Publication of GB2453084A publication Critical patent/GB2453084A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Kalata B1 based polypeptides comprising viral NS3 serine protease recognition sequence on a cyclic molecular framework for use as anti-virals in the treatment of dengue fever.
GB0900707A 2006-06-19 2007-06-19 Novel polypeptides for an anti-viral treatment Withdrawn GB2453084A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG200604180-0A SG138488A1 (en) 2006-06-19 2006-06-19 Novel polypeptides for anti-viral treatment
PCT/SG2007/000168 WO2007149052A1 (en) 2006-06-19 2007-06-19 Novel polypeptides for anti-viral treatment

Publications (2)

Publication Number Publication Date
GB0900707D0 GB0900707D0 (en) 2009-03-04
GB2453084A true GB2453084A (en) 2009-03-25

Family

ID=38833697

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0900707A Withdrawn GB2453084A (en) 2006-06-19 2007-06-19 Novel polypeptides for an anti-viral treatment

Country Status (3)

Country Link
GB (1) GB2453084A (en)
SG (1) SG138488A1 (en)
WO (1) WO2007149052A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4378534A3 (en) 2011-12-22 2024-08-07 Medizinische Universität Wien Cyclotides as immunosuppressive agents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027147A1 (en) * 1999-10-13 2001-04-19 The University Of Queensland A novel molecule
WO2001034829A2 (en) * 1999-11-05 2001-05-17 The University Of Queensland Nucleic acid sequence which encodes for an amino acid sequence capable of being cyclized within a cell or cell membrane

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027147A1 (en) * 1999-10-13 2001-04-19 The University Of Queensland A novel molecule
WO2001034829A2 (en) * 1999-11-05 2001-05-17 The University Of Queensland Nucleic acid sequence which encodes for an amino acid sequence capable of being cyclized within a cell or cell membrane

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FEBS Letters (2004); Vol 574, pp 69-72, "The role of the cyclic peptide...", Daly et al *

Also Published As

Publication number Publication date
SG138488A1 (en) 2008-01-28
WO2007149052A1 (en) 2007-12-27
GB0900707D0 (en) 2009-03-04

Similar Documents

Publication Publication Date Title
ES2336009T8 (en) HCV serine protease NS-3 inhibitors
DK1924593T3 (en) HCV NS3 protease inhibitors
SG155211A1 (en) Peptide
EP2076278A4 (en) HCV NS3 PROTEASE INHIBITORS
DE602006009226D1 (en) NEEDLE-FREE TRANSPARENT TRANSPORT DEVICE
IL189166A0 (en) Macrocyclic peptides as hcv ns3 protease inhibitors
EA200901109A1 (en) APPLICATION OF N-PHYLENAMIDINE AS HERBICIDES
CL2012000919A1 (en) Composition comprising a compound derived from methoxycarbonyl-amino-methylbutanoyl-pyrrolidinyl-imidazole of formula I, specific inhibitor of hcv ns5a, and an oxo-pyrrolidine-quinoline derived compound of formula II, inhibitor of protease ns3 of hcv; and use in the treatment of hepatitis c.
GB0700909D0 (en) Novel antigen-binding polypeptides and their uses
UY3743Q (en) HAND VACUUM CLEANER (PORTABLE)
EP1931702A4 (en) SILK PROTEINS
SG165353A1 (en) Improved human interferon molecules and their uses
ITRM20040323A1 (en) OXYGEN CONSUMPTION MEASURING DEVICE.
NO20081127L (en) Vaccination against Dengue virus infection
BRPI0923184A2 (en) hcv ns3 protease inhibitors
CL2008003267A1 (en) Compounds derived from pyrrolidine fused macrocycles, inhibitors of serine protease ns3; pharmaceutical composition comprising one of the compounds; and the use of the compounds in the preparation of medicaments for the treatment of hepatitis c.
GT200800005S (en) "ABSOLUT FRAMED" BOTTLE DESIGN.
ATE547425T1 (en) OPTIMIZED DENGUE VIRUS ENTRY-INHIBITING PEPTIDE (DN81)
ZA200800072B (en) HCV NS3 Protease inhibitors
DE602005007364D1 (en) cyclic peptides,
GB2453084A (en) Novel polypeptides for an anti-viral treatment
HRP20110093T4 (en) ESCITALOPRAM CRYSTAL DATABASE AND ORODISPERSIBLE TABLES CONTAINING ESCITALOPRAM DATABASE
ITMI20041440A1 (en) ANALOGUE PEPTIDES OF PTH-1-11
ZA200800507B (en) Macrocyclic peptides as HCV NS3 protease inhibitors
FR2887090B1 (en) XOR CIRCUIT.

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)